integrated Filing
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kerala Ayurveda Ltd reported FY25 standalone revenue from operations of Rs. 7,268.92 lakhs, up about 6.8% from Rs. 6,803.65 lakhs (restated) in FY24. However, the company swung to a sharp net loss of Rs. 1,377.98 lakhs in FY25 versus a Rs. 5.32 lakh profit a year ago, with EPS at Rs. (114.52). Total expenses surged to Rs. 9,134 lakhs, driven by employee costs jumping to Rs. 3,551 lakhs and a Rs. 622 lakh ESOP charge. Cash and cash equivalents collapsed from Rs. 1,649 lakhs to just Rs. 36 lakhs, while total borrowings stand at Rs. 5,411 lakhs against equity of Rs. 2,513 lakhs. Statutory auditor G. Joseph & Associates issued a Qualified Opinion due to an unconfirmed Rs. 3.85 lakh bank balance and an Emphasis of Matter on the restatement of prior period figures under Ind AS 8 covering lease assets, deferred expenditure, loans to subsidiaries, investments, and trade receivables. The board also approved a new Company Secretary, new internal auditor, and a near-doubling of the ESOP pool from 6.66 lakh to 12.03 lakh shares, with an EGM called for June 18, 2025 to approve related-party transactions with Ayurvedagram Heritage Wellness Centre.
Shareholders should note the significant FY25 loss, prior-period restatement that shaved nearly Rs. 960 lakhs off previously reported equity, and a Qualified audit opinion — though the qualification itself is minor (Rs. 3.85 lakhs). The combination of surging losses, depleted cash, high borrowings, related-party dealings needing shareholder approval, and a potential equity dilution from the expanded ESOP pool is a mixed-to-negative signal for the stock in the near term.